Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ImmunoGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

ImmunoGen şirketinin toplam hissedar öz sermayesi $561.6M ve toplam borcu $72.1M olup, bu da borç-öz sermaye oranını 12.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $822.1M ve $260.5M dir.

Anahtar bilgiler

12.8%

Borç/özkaynak oranı

US$72.11m

Borç

Faiz karşılama oranı	n/a
Nakit	US$605.54m
Eşitlik	US$561.60m
Toplam yükümlülükler	US$260.51m
Toplam varlıklar	US$822.10m

Son finansal sağlık güncellemeleri

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

Recent updates

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Jan 09

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Dec 22

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

Aug 06

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Jul 20

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

May 03

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

Apr 18

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMGN 'nin kısa vadeli varlıkları ( $766.9M ) kısa vadeli yükümlülüklerini ( $134.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMGN şirketinin kısa vadeli varlıkları ( $766.9M ) uzun vadeli yükümlülüklerini ( $125.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMGN şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: IMGN şirketinin borç/öz sermaye oranı son 5 yılda 4.4% seviyesinden 12.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IMGN şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: IMGN tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

ImmunoGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ImmunoGen Files Form 15

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Forecast breakeven date pushed back to 2024

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Insider notifies of intention to sell stock

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Insider exercised options and sold US$3.0m worth of stock

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

Price target increased by 10% to US$25.39

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Insider exercised options and sold US$1.9m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Insider notifies of intention to sell stock

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.0% to US$19.00

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Price target increased by 13% to US$16.20

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

Consensus revenue estimates increase by 80%

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Price target increased by 18% to US$14.10

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin